Univariate analysis of the effect of clinical parameters, BM LGALS3 expression, and molecular alterations on overall survival in patients with AML
| Variable . | No. of patients . | Overall survival (months) . | |
|---|---|---|---|
| Median* . | P value . | ||
| Age, years | .001 | ||
| ≤50 | 133 | 39.8 | |
| >50 | 78 | 12.3 ± 3 | |
| Sex | .677 | ||
| Male | 110 | 25 ± 7.7 | |
| Female | 101 | 18 ± 5.3 | |
| WBC | .046 | ||
| ≤50000/μL | 149 | 26 ± 16.6 | |
| >50000/μL | 62 | 15.5 ± 5.2 | |
| Karyotype† | .013 | ||
| Favorable | 33 | NR | |
| Intermediate | 152 | 22 ± 9.5 | |
| Unfavorable | 18 | 9.5 ± 1.5 | |
| LGALS3 | .02 | ||
| Lower expression | 120 | 39.8 ± 14.4 | |
| Higher expression | 91 | 16.3 ± 3.4 | |
| CEBPA | .008 | ||
| Double mutation | 28 | NR | |
| Others | 183 | 19 ± 3 | |
| NPM1+/ FLT3-ITD- | .038 | ||
| Yes | 26 | 95 | |
| Others | 185 | 22 ± 3.4 | |
| AML1/RUNX1 | .001 | ||
| Mutated | 21 | 8 ± 1 | |
| Wild | 190 | 25.5 ± 14 | |
| WT1 | .024 | ||
| Mutated | 21 | 11 ± 1.4 | |
| Wild | 190 | 25 ± 15.4 | |
| MLL-PTD | .004 | ||
| Yes | 10 | 10.5 ± 6.1 | |
| No | 201 | 25 ± 7.6 | |
| RAS | .89 | ||
| Mutated | 33 | 17 ± 7.3 | |
| Wild | 178 | 23.5 ± 7 | |
| PTPN11 | .21 | ||
| Mutated | 7 | 17.5 ± 13.6 | |
| Wild | 204 | 23.5 ± 6.8 | |
| FLT3-TKD | .542 | ||
| Yes | 17 | 39.8 | |
| No | 194 | 23 ± 3.4 | |
| KIT | .525 | ||
| Mutated | 8 | 12 ± 1.9 | |
| Wild | 203 | 25 ± 7.3 | |
| ASXL1 | .697 | ||
| Mutated | 14 | 26 ± 5.7 | |
| Wild | 197 | 23 ± 7.6 | |
| IDH1 | .798 | ||
| Mutated | 15 | 19 ± 1.8 | |
| Wild | 196 | 25 ± 7.4 | |
| IDH2 | .116 | ||
| Mutated | 27 | NR | |
| Wild | 184 | 22 ± 3.4 | |
| TET2 | .547 | ||
| Mutated | 22 | 13 ± 10.9 | |
| Wild | 189 | 23.5 ± 7 | |
| Variable . | No. of patients . | Overall survival (months) . | |
|---|---|---|---|
| Median* . | P value . | ||
| Age, years | .001 | ||
| ≤50 | 133 | 39.8 | |
| >50 | 78 | 12.3 ± 3 | |
| Sex | .677 | ||
| Male | 110 | 25 ± 7.7 | |
| Female | 101 | 18 ± 5.3 | |
| WBC | .046 | ||
| ≤50000/μL | 149 | 26 ± 16.6 | |
| >50000/μL | 62 | 15.5 ± 5.2 | |
| Karyotype† | .013 | ||
| Favorable | 33 | NR | |
| Intermediate | 152 | 22 ± 9.5 | |
| Unfavorable | 18 | 9.5 ± 1.5 | |
| LGALS3 | .02 | ||
| Lower expression | 120 | 39.8 ± 14.4 | |
| Higher expression | 91 | 16.3 ± 3.4 | |
| CEBPA | .008 | ||
| Double mutation | 28 | NR | |
| Others | 183 | 19 ± 3 | |
| NPM1+/ FLT3-ITD- | .038 | ||
| Yes | 26 | 95 | |
| Others | 185 | 22 ± 3.4 | |
| AML1/RUNX1 | .001 | ||
| Mutated | 21 | 8 ± 1 | |
| Wild | 190 | 25.5 ± 14 | |
| WT1 | .024 | ||
| Mutated | 21 | 11 ± 1.4 | |
| Wild | 190 | 25 ± 15.4 | |
| MLL-PTD | .004 | ||
| Yes | 10 | 10.5 ± 6.1 | |
| No | 201 | 25 ± 7.6 | |
| RAS | .89 | ||
| Mutated | 33 | 17 ± 7.3 | |
| Wild | 178 | 23.5 ± 7 | |
| PTPN11 | .21 | ||
| Mutated | 7 | 17.5 ± 13.6 | |
| Wild | 204 | 23.5 ± 6.8 | |
| FLT3-TKD | .542 | ||
| Yes | 17 | 39.8 | |
| No | 194 | 23 ± 3.4 | |
| KIT | .525 | ||
| Mutated | 8 | 12 ± 1.9 | |
| Wild | 203 | 25 ± 7.3 | |
| ASXL1 | .697 | ||
| Mutated | 14 | 26 ± 5.7 | |
| Wild | 197 | 23 ± 7.6 | |
| IDH1 | .798 | ||
| Mutated | 15 | 19 ± 1.8 | |
| Wild | 196 | 25 ± 7.4 | |
| IDH2 | .116 | ||
| Mutated | 27 | NR | |
| Wild | 184 | 22 ± 3.4 | |
| TET2 | .547 | ||
| Mutated | 22 | 13 ± 10.9 | |
| Wild | 189 | 23.5 ± 7 | |
Two hundred eleven patients with non-M3 AML who received conventional intensive induction chemotherapy, and then consolidation chemotherapy if CR was achieved, were included in the analysis.
NR, not reached.
Median ± standard deviation.
Eight patients without chromosome data at diagnosis were excluded for analysis. Favorable, t(8;21), inv(16); unfavorable, −7, del(7q), −5, del(5q), 3q abnormality, complex abnormalities; intermediate, normal karyotype and other abnormalities.